|
Michael F. Sexton
Partner
|
|
|
|
Michael F. Sexton focuses his practice on representing pharmaceutical manufacturers, medical device companies, biotechnology companies and life sciences venture capital firms in connection with licensing and collaboration agreements, financings, regulatory advice and general corporate matters.
He also counsels academic medical centers, hospitals, other health care providers and managed care organizations on a variety of health care regulatory matters and transactions.
Mike is a partner in the firm's Life Sciences group and Health Care group.
Pharmaceuticals/Biotechnology
- Represented Johnson & Johnson in numerous licensing, collaboration and other transactions, including:
- Janssen Biotech’s agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.
- Centocor Ortho Biotech’s settlement agreement to amend the distribution rights to REMICADE® (infliximab) and SIMPONI® (golimumab) with Merck & Co and its subsidiary Schering-Plough.
- Various collaboration and co-promotion agreements with Millennium Pharmaceuticals and its affiliate Takeda Pharmaceutical Company relating to the development and commercialization of VELCADE® (bortezomib).
Assisted Pfizer in numerous pharmaceutical and biotech licensing, collaboration and other transactions, including:
- Sale and license of its generic Advair Diskus product development program and related technology, assets and employees to Mylan Inc.]
- Development, commercialization and supply agreement with Biocon Ltd. under which Pfizer licensed the rights to commercialize Biocon’s biosimilar insulin and insulin analog products worldwide.
- Worldwide (excluding Israel) license of rights from Protalix Ltd., to develop and commercialize a potential product for the treatment of Gaucher’s disease.
Assisted various global pharmaceutical and biotech manufacturers with manufacturing and supply agreements, distribution agreements and authorized generic agreements.
Regularly provides advice to pharmaceutical companies on health care regulatory compliance matters.
Medical Devices
- Represented Salient Surgical Technologies from its inception through its sale to Medtronic for $525 million in 2011.
- Assist other venture capital-backed medical device companies, such as Verax Biomedical, with financings and general corporate matters.
- Regularly provide health care regulatory compliance advice to a global medical device manufacturer.
Life Sciences Venture Capital
Represented RiverVest Venture Partners on numerous investments, including:
- Founding of and investments in Excaliard Pharmaceuticals, which was sold to Pfizer in 2011.
- Founding of and investments in Lutonix, which was sold to Bard for $225 million in 2011.
- Investments in other medical device, biotech and high tech companies
Health Care Services and Managed Care
- Assisted H. Lee Moffitt Cancer Center in its tumor tissue banking and genomic sequencing research collaboration with Merck & Co.
- Provided health care regulatory advice to Express Scripts on various transactions, including its $4.6 billion acquisition of NextRx from WellPoint.
- Represented academic medical centers and other health care providers, such as Daughters of Charity Health System, Stanford and Yale, on regulatory compliance matters, corporate restructurings, affiliations and other transactions.
Honors & Awards
- The Best Lawyers in America (2007-2012)
Clerkships
- Honorable Levin H. Campbell, U.S. Court of Appeals for the First Circuit
©1996-2012 Ropes & Gray LLP. All rights reserved.
|
|
Education
-
JD, cum laude, Harvard Law School, 1992; Editor, Harvard Law Review
-
BA, magna cum laude, Amherst College, 1987; Phi Beta Kappa
|
|